Several osteoporosis medications have no reported link to hair loss in clinical trials. The bone-building drugs abaloparatide (Tymlos), teriparatide (Forteo), and romosozumab (Evenity) did not produce hair loss as a side effect in their clinical studies. If you’re concerned about thinning hair while treating osteoporosis, these are the options with the cleanest track record on this front.
Bone-Building Drugs With No Hair Loss Reports
Osteoporosis medications fall into two broad camps: those that slow bone breakdown and those that actively build new bone. The bone-building (anabolic) drugs are the ones least associated with hair loss.
Abaloparatide (Tymlos) and teriparatide (Forteo) both work by stimulating your body to form new bone. Hair loss was not reported in clinical trials for either drug. Romosozumab (Evenity), which works through a different mechanism by blocking a protein that limits bone growth, also showed no hair loss in its Phase 3 trials. These three medications are typically prescribed for people with severe osteoporosis or a high fracture risk, and they’re given as injections rather than pills.
The catch is that anabolic drugs are usually limited to a treatment window of one to two years, after which you’ll need to transition to a maintenance medication. So while they’re the safest choices for your hair, they aren’t lifelong options.
Which Medications Are Linked to Hair Loss
Bisphosphonates are the most widely prescribed class of osteoporosis drugs, and they’re the group most commonly associated with hair thinning. Alendronate (Fosamax) in particular has been linked to hair loss in post-marketing reports. Other bisphosphonates, including risedronate and zoledronic acid, belong to the same drug class and carry a similar potential risk, though reports are less frequent.
Selective estrogen receptor modulators (SERMs) like tamoxifen are also known to cause hair thinning in some users. These drugs reduce estrogenic effects on the body, which can push hair follicles into their resting phase prematurely. When a large number of follicles enter the resting phase at once, you notice increased shedding weeks to months later. Raloxifene (Evista), another SERM used specifically for osteoporosis in postmenopausal women, works through a similar mechanism, though hair loss data specific to raloxifene is limited compared to tamoxifen.
Denosumab: A Gray Area
Denosumab (Prolia) sits in an uncertain middle ground. In one phase 1 trial, 11% of participants experienced hair loss, but every person in that study was also receiving chemotherapy or hormonal therapy for breast cancer. That makes it impossible to pin the hair loss on denosumab itself. There have also been isolated case reports of a patchy hair loss condition developing after denosumab treatment, but these are rare and don’t establish a clear pattern.
For most people taking denosumab purely for osteoporosis, hair loss does not appear to be a common concern. But if you’ve already experienced hair thinning on another medication and are weighing your options, it’s worth knowing the data isn’t perfectly clean.
Vitamin D Deficiency May Be the Real Culprit
Before assuming your medication is causing hair loss, consider a factor that’s easy to overlook: vitamin D levels. People with osteoporosis frequently have low vitamin D, and vitamin D plays a direct role in hair follicle growth and cycling. Research shows an inverse relationship between vitamin D levels and several types of non-scarring hair loss, meaning the lower your vitamin D, the more likely you are to experience thinning.
This matters because you might start an osteoporosis medication and notice hair loss around the same time, then blame the drug when the underlying deficiency is actually responsible. A simple blood test can check your levels. If your vitamin D is low, correcting it through supplementation may improve both your bone health and your hair, regardless of which osteoporosis drug you’re taking.
What to Expect if You Switch Medications
Drug-related hair loss from osteoporosis medications is generally a type called telogen effluvium, where follicles are pushed into their resting phase too early. The good news is that this type of hair loss is typically reversible. Once the triggering medication is stopped or switched, hair follicles gradually re-enter their growth phase. Most people begin to see regrowth within three to six months, though it can take up to a year for your hair to return to its previous thickness.
If you’re currently on a bisphosphonate and noticing hair thinning, switching to an anabolic agent like teriparatide or abaloparatide removes the hair loss concern while also actively building bone density. The transition needs to be managed carefully, since stopping certain medications (especially denosumab) without starting another can lead to rapid bone loss. Your prescriber can map out a sequence that protects both your bones and your hair.